This study aimed to explore the effect of intravenous thrombolysis with
alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute
cerebral infarction. A total of 120 patients with acute
cerebral infarction were divided into two groups by the random number table method, with 60 patients in each group: observation group (intravenous thrombolysis with
alteplase) and control group (intravenous thrombolysis with
batroxobin). The clinical efficacy after a 14-day treatment was observed. Serum
C-reactive protein (CRP),
tumor necrosis factor α (TNF-α),
interleukin-6 (IL-6), CD62p,
GMP-140, and
neuron-specific enolase (NSE) were measured. Scores of National Institutes of Health
Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) were determined. The total effective rate in the observation group was 81.67%, which was higher than the 61.67% in the control group (P<0.05). The improvement of inflammatory factors (CRP, TNF-α, IL-6, CD62p, GMP-140, and NSE), NIHSS, MMSE, and MoCA in the observation group was superior to that in the control group (all P<0.05). The modified Rankin scale at three months after hospital discharge in the observation group was lower than that in the control group (P<0.01). Intravenous thrombolysis with
alteplase for acute
cerebral infarction can enhance the clinical efficacy, alleviate inflammatory response and
brain injury, and improve cognitive function, which is worthy of further clinical application and study.